Log in
NASDAQ:GNFT

GENFIT S A/ADR Stock Forecast, Price & News

$4.19
+0.52 (+14.17 %)
(As of 09/25/2020 12:00 AM ET)
Add
Compare
Today's Range
$3.93
Now: $4.19
$4.58
50-Day Range
$3.67
MA: $4.84
$5.21
52-Week Range
$3.65
Now: $4.19
$22.48
Volume209,907 shs
Average Volume72,985 shs
Market Capitalization$158.52 million
P/E RatioN/A
Dividend YieldN/A
Beta0.68
Genfit SA, a biopharmaceutical company, develops therapeutic and diagnostic solutions for metabolic, inflammatory, and autoimmune or fibrotic diseases affecting primarily the liver and gastro-enterology. The company's lead products include Elafibranor, which is in pivotal Phase 3 clinical trials for the treatment of nonalcoholic steatohepatitis (NASH), as well as in Phase 2 study in patients with primary biliary cholangitis; and Nitazoxanide that is in Phase 2 proof-of-concept clinical trial for the treatment of NASH-induced significant or severe fibrosis. It is also developing in-vitro diagnostic test for the identification of patients with NASH; and TGFTX1 preclinical program for treating psoriasis or respiratory conditions, such as neutrophilic asthma, chronic obstructive pulmonary disease (COPD), and the asthma-COPD overlap syndrome. Genfit SA was founded in 1999 and is headquartered in Loos, France.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.1Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.26 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:GNFT
CUSIPN/A
CIKN/A
Phone33-3-20-16-40-00

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$45.88 million
Book Value$2.49 per share

Profitability

Miscellaneous

Employees148
Market Cap$158.52 million
Next Earnings DateN/A
OptionableNot Optionable
$4.19
+0.52 (+14.17 %)
(As of 09/25/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive GNFT News and Ratings via Email

Sign-up to receive the latest news and ratings for GNFT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











GENFIT S A/ADR (NASDAQ:GNFT) Frequently Asked Questions

How has GENFIT S A/ADR's stock been impacted by Coronavirus (COVID-19)?

GENFIT S A/ADR's stock was trading at $14.23 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, GNFT stock has decreased by 70.6% and is now trading at $4.19.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of GENFIT S A/ADR?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GENFIT S A/ADR in the last year. There are currently 3 sell ratings, 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for GENFIT S A/ADR
.

What price target have analysts set for GNFT?

10 Wall Street analysts have issued 1 year price objectives for GENFIT S A/ADR's shares. Their forecasts range from $7.00 to $174.00. On average, they expect GENFIT S A/ADR's stock price to reach $44.60 in the next twelve months. This suggests a possible upside of 964.4% from the stock's current price.
View analysts' price targets for GENFIT S A/ADR
.

Are investors shorting GENFIT S A/ADR?

GENFIT S A/ADR saw a increase in short interest in September. As of September 15th, there was short interest totaling 13,800 shares, an increase of 42.3% from the August 31st total of 9,700 shares. Based on an average daily trading volume, of 32,600 shares, the short-interest ratio is currently 0.4 days.
View GENFIT S A/ADR's Short Interest
.

Who are some of GENFIT S A/ADR's key competitors?

What other stocks do shareholders of GENFIT S A/ADR own?

Who are GENFIT S A/ADR's key executives?

GENFIT S A/ADR's management team includes the following people:
  • Mr. Jean-François Mouney, Co-Founder, CEO & Chairman (Age 64)
  • Ms. Nathalie Huitorel, Exec. VP, Chief Financial & Admin. Officer (Age 58)
  • Dr. Dean W. Hum, Chief Operating Officer (Age 57)
  • Prof. Bart Staels, Co-Founder & Pres of the Scientific Advisory Board (Age 56)
  • Mr. Laurent Lannoo, Corp. Sec. & Director of Legal Affairs (Age 49)

When did GENFIT S A/ADR IPO?

(GNFT) raised $132 million in an initial public offering (IPO) on Wednesday, March 27th 2019. The company issued 5,000,000 shares at $26.33 per share. SVB Leerink and Barclays acted as the underwriters for the IPO and Bryan, Garnier, Natixis, Roth Capital Partners and H.C. Wainwright & Co. were co-managers.

What is GENFIT S A/ADR's stock symbol?

GENFIT S A/ADR trades on the NASDAQ under the ticker symbol "GNFT."

Who are GENFIT S A/ADR's major shareholders?

GENFIT S A/ADR's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Ikarian Capital LLC (0.17%).

Which institutional investors are buying GENFIT S A/ADR stock?

GNFT stock was purchased by a variety of institutional investors in the last quarter, including Ikarian Capital LLC.

How do I buy shares of GENFIT S A/ADR?

Shares of GNFT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is GENFIT S A/ADR's stock price today?

One share of GNFT stock can currently be purchased for approximately $4.19.

How big of a company is GENFIT S A/ADR?

GENFIT S A/ADR has a market capitalization of $158.52 million and generates $45.88 million in revenue each year. The company earns $-72,960,000.00 in net income (profit) each year or ($1.97) on an earnings per share basis. GENFIT S A/ADR employs 148 workers across the globe.

What is GENFIT S A/ADR's official website?

The official website for GENFIT S A/ADR is www.genfit.com.

How can I contact GENFIT S A/ADR?

GENFIT S A/ADR's mailing address is PARC 885 AVENUE EUGENE AVINEE, LOOS I0, 59120. The company can be reached via phone at 33-3-20-16-40-00 or via email at [email protected]

This page was last updated on 9/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.